Published in Pharmacol Biochem Behav on April 18, 2013
Intra-nucleus accumbens shell injections of R(+)- and S(-)-baclofen bidirectionally alter binge-like ethanol, but not saccharin, intake in C57Bl/6J mice. Behav Brain Res (2014) 0.84
Neuronal Nicotinic Acetylcholine Receptor Modulators Reduce Sugar Intake. PLoS One (2016) 0.78
Recent developments in novel antidepressants targeting α4β2-nicotinic acetylcholine receptors. J Med Chem (2014) 0.77
Differential Gene Expression Profile in the Rat Caudal Vestibular Nucleus is Associated with Individual Differences in Motion Sickness Susceptibility. PLoS One (2015) 0.77
Anxiolytic- and antidepressant-like effects of the methadone metabolite 2-ethyl-5-methyl-3,3-diphenyl-1-pyrroline (EMDP). Neuropharmacology (2015) 0.77
Critical needs in drug discovery for cessation of alcohol and nicotine polysubstance abuse. Prog Neuropsychopharmacol Biol Psychiatry (2015) 0.75
Blockade of cholinergic transmission elicits somatic signs in nicotine-naïve adolescent rats. Front Pharmacol (2015) 0.75
Orthosteric and Allosteric Ligands of Nicotinic Acetylcholine Receptors for Smoking Cessation. Front Mol Neurosci (2015) 0.75
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem (1976) 903.81
Some quantitative uses of drug antagonists. Br J Pharmacol Chemother (1959) 41.90
A study of the desensitization produced by acetylcholine at the motor end-plate. J Physiol (1957) 15.07
Depression: a new animal model sensitive to antidepressant treatments. Nature (1977) 8.76
Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu Rev Pharmacol Toxicol (2007) 5.48
Conditioned place preference: what does it add to our preclinical understanding of drug reward? Psychopharmacology (Berl) (2000) 4.95
Evaluation of a simple model of ethanol drinking to intoxication in C57BL/6J mice. Physiol Behav (2005) 4.79
The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev (2005) 4.64
Development and validation of the Biphasic Alcohol Effects Scale. Alcohol Clin Exp Res (1993) 4.03
New insights into BDNF function in depression and anxiety. Nat Neurosci (2007) 3.94
Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology (Berl) (2005) 3.92
Dopamine and drug addiction: the nucleus accumbens shell connection. Neuropharmacology (2004) 3.52
Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res (2002) 3.31
Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol (1981) 3.18
Neuronal nicotinic receptors: from structure to pathology. Prog Neurobiol (2004) 3.17
Molecular and physiological diversity of nicotinic acetylcholine receptors in the midbrain dopaminergic nuclei. J Neurosci (2001) 3.05
Neurobiological similarities in depression and drug dependence: a self-medication hypothesis. Neuropsychopharmacology (1998) 2.96
It is not "either/or": activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood. Prog Neurobiol (2007) 2.85
Cigarette smoking: implications for psychiatric illness. Am J Psychiatry (1993) 2.82
Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatry (2003) 2.82
Forced swimming test in mice: a review of antidepressant activity. Psychopharmacology (Berl) (2004) 2.74
Studies on the mechanism of action of acetylcholine antagonists on rat parasympathetic ganglion cells. J Physiol (1979) 2.67
In search of a depressed mouse: utility of models for studying depression-related behavior in genetically modified mice. Mol Psychiatry (2004) 2.55
Desensitization of neuronal nicotinic receptors. J Neurobiol (2002) 2.49
Intravenous nicotine self-administration in rats: effects of mecamylamine, hexamethonium and naloxone. Psychopharmacology (Berl) (2005) 2.41
Role of dopamine in the behavioural actions of nicotine related to addiction. Eur J Pharmacol (2000) 2.38
Pharmacological characterization of recombinant human neuronal nicotinic acetylcholine receptors h alpha 2 beta 2, h alpha 2 beta 4, h alpha 3 beta 2, h alpha 3 beta 4, h alpha 4 beta 2, h alpha 4 beta 4 and h alpha 7 expressed in Xenopus oocytes. J Pharmacol Exp Ther (1997) 2.30
Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms. Arch Gen Psychiatry (2005) 2.28
Desensitization of nicotinic ACh receptors: shaping cholinergic signaling. Trends Neurosci (2005) 2.20
Association of attention-deficit/hyperactivity disorder symptoms with levels of cigarette smoking in a community sample of adolescents. J Am Acad Child Adolesc Psychiatry (2002) 2.19
Both alpha- and beta-subunits contribute to the agonist sensitivity of neuronal nicotinic acetylcholine receptors. J Neurosci (1991) 2.18
Cigarette smoking in adult patients diagnosed with attention deficit hyperactivity disorder. J Subst Abuse (1995) 2.10
Nicotinic acetylcholine receptors as targets for antidepressants. Mol Psychiatry (2002) 2.02
Nicotinic acetylcholine receptors: from structure to brain function. Rev Physiol Biochem Pharmacol (2003) 1.99
A cholinergic-adrenergic hypothesis of mania and depression. Lancet (1972) 1.97
Ca2+ permeability of the (alpha4)3(beta2)2 stoichiometry greatly exceeds that of (alpha4)2(beta2)3 human acetylcholine receptors. Mol Pharmacol (2006) 1.91
Nicotinic receptor subtypes and cognitive function. J Neurobiol (2002) 1.86
Serum levels of brain-derived neurotrophic factor in major depressive disorder: state-trait issues, clinical features and pharmacological treatment. Mol Psychiatry (2010) 1.79
Analysis of mecamylamine stereoisomers on human nicotinic receptor subtypes. J Pharmacol Exp Ther (2001) 1.74
Ganglionic blocking properties of 3-methylaminoisocamphane hydrochloride (mecamylamine): a secondary amine. J Pharmacol Exp Ther (1956) 1.70
Nicotine-induced increase in neuronal nicotinic receptors results from a decrease in the rate of receptor turnover. Mol Pharmacol (1994) 1.68
Neuronal nicotinic receptors: a perspective on two decades of drug discovery research. Biochem Pharmacol (2007) 1.63
Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology (1996) 1.62
The channel-blocking action of methonium compounds on rat submandibular ganglion cells. Br J Pharmacol (1984) 1.60
Neuronal nicotinic acetylcholine receptor subunit knockout mice: physiological and behavioral phenotypes and possible clinical implications. Pharmacol Ther (2002) 1.60
Suppression of methamphetamine-seeking behavior by nicotinic agonists. Proc Natl Acad Sci U S A (2006) 1.56
Neurochemical and behavioral studies on ethanol and nicotine interactions. Neurosci Biobehav Rev (2004) 1.56
Biological processes underlying co-use of alcohol and nicotine: neuronal mechanisms, cross-tolerance, and genetic factors. Alcohol Res Health (2006) 1.55
Regulation of drug-taking and -seeking behaviors by neuroadaptations in the mesolimbic dopamine system. Neuropharmacology (2004) 1.54
Nicotine self-administration in rats: strain and nicotine pre-exposure effects on acquisition. Psychopharmacology (Berl) (1997) 1.54
Nicotine enhances responding with conditioned reinforcement. Psychopharmacology (Berl) (2003) 1.52
High-affinity nicotinic acetylcholine receptors are required for antidepressant effects of amitriptyline on behavior and hippocampal cell proliferation. Biol Psychiatry (2004) 1.49
A randomized, controlled trial to assess the efficacy and safety of a transdermal delivery system of nicotine/mecamylamine in cigarette smokers. Addiction (2007) 1.48
Characterization of nicotinic receptor-mediated [3H]dopamine release from synaptosomes prepared from mouse striatum. J Neurochem (1992) 1.45
The nicotinic antagonist mecamylamine has antidepressant-like effects in wild-type but not beta2- or alpha7-nicotinic acetylcholine receptor subunit knockout mice. Psychopharmacology (Berl) (2006) 1.45
Distinct contributions of nicotinic acetylcholine receptor subunit alpha4 and subunit alpha6 to the reinforcing effects of nicotine. Proc Natl Acad Sci U S A (2011) 1.44
Involvement of nicotinic receptors in alcohol self-administration. Alcohol Clin Exp Res (2000) 1.43
Desensitization of nicotinic acetylcholine receptors as a strategy for drug development. J Pharmacol Exp Ther (2008) 1.43
Pharmacologic characterization of nicotine-induced conditioned place preference. Pharmacol Biochem Behav (1985) 1.42
Expression of functional nicotinic acetylcholine receptors in rat urinary bladder epithelial cells. Am J Physiol Renal Physiol (2005) 1.42
Treatment-resistant depression. Am Fam Physician (2009) 1.41
Nicotinic antagonist augmentation of selective serotonin reuptake inhibitor-refractory major depressive disorder: a preliminary study. J Clin Psychopharmacol (2008) 1.41
Brain neuronal nicotinic receptors as new targets for drug discovery. Curr Pharm Des (2006) 1.41
Evaluation of antidepressant-related behavioral responses in mice lacking the serotonin transporter. Neuropsychopharmacology (2002) 1.39
Nicotine-mecamylamine treatment for smoking cessation: the role of pre-cessation therapy. Exp Clin Psychopharmacol (1998) 1.38
Extinguishing the rewarding value of smoke cues: pharmacological and behavioral treatments. Nicotine Tob Res (2004) 1.38
Regulation of nicotinic acetylcholine receptor numbers and function by chronic nicotine exposure. Curr Drug Targets CNS Neurol Disord (2002) 1.38
Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clin Pharmacol Ther (1994) 1.38
Neuroprotection via nAChRs: the role of nAChRs in neurodegenerative disorders such as Alzheimer's and Parkinson's disease. Front Biosci (2008) 1.38
Voluntary ethanol intake in the rat and the associated accumbal dopamine overflow are blocked by ventral tegmental mecamylamine. Eur J Pharmacol (1998) 1.37
Acetylcholine-evoked currents in cultured neurones dissociated from rat parasympathetic cardiac ganglia. J Physiol (1991) 1.35
Effect of a novel nicotinic receptor antagonist, N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide, on nicotine self-administration and hyperactivity in rats. Psychopharmacology (Berl) (2005) 1.35
Nicotine place preference in the mouse: influences of prior handling, dose and strain and attenuation by nicotinic receptor antagonists. Psychopharmacology (Berl) (2006) 1.34
Cigarette smoking and major depression. J Addict Dis (1998) 1.34
Conditioned taste aversions and drugs of abuse: a reinterpretation. Behav Neurosci (1997) 1.34
Alpha3beta4 subunit-containing nicotinic receptors dominate function in rat medial habenula neurons. Neuropharmacology (1999) 1.34
Alcohol's actions on neuronal nicotinic acetylcholine receptors. Alcohol Res Health (2006) 1.33
TC-5214 (S-(+)-mecamylamine): a neuronal nicotinic receptor modulator with antidepressant activity. CNS Neurosci Ther (2008) 1.33
Effects of nicotine in experimental animals and humans: an update on addictive properties. Handb Exp Pharmacol (2009) 1.31
Enantioselective aspects of drug action and disposition: therapeutic pitfalls. J Pharm Sci (1989) 1.31
The Flinders sensitive line rats: a genetic animal model of depression. Neurosci Biobehav Rev (1993) 1.31
Individual differences in the biphasic effects of ethanol. Alcohol Clin Exp Res (1998) 1.29
Different types of blockade of crustacean acetylcholine-induced currents. J Physiol (1983) 1.29
Smoking kills (alcoholics)! shouldn't we do something about it? Alcohol Alcohol (2007) 1.28
Modulation of ethanol drinking-in-the-dark by mecamylamine and nicotinic acetylcholine receptor agonists in C57BL/6J mice. Psychopharmacology (Berl) (2009) 1.26
Competitive neuronal nicotinic receptor antagonists: a new direction for drug discovery. J Pharmacol Exp Ther (2001) 1.25
Extending the analysis of nicotinic receptor antagonists with the study of alpha6 nicotinic receptor subunit chimeras. Neuropharmacology (2008) 1.25
Nicotinic acetylcholine receptors in the ventral tegmental area mediate the dopamine activating and reinforcing properties of ethanol cues. Psychopharmacology (Berl) (2007) 1.22
A comparison of nicotine and cocaine self-administration in the dog: fixed-ratio and progressive-ratio schedules of intravenous drug infusion. J Pharmacol Exp Ther (1983) 1.22
Dependence of nicotinic acetylcholine receptor recovery from desensitization on the duration of agonist exposure. J Pharmacol Exp Ther (1999) 1.22
A general theory of aversion learning. Ann N Y Acad Sci (1985) 1.21
Reduction in p140-TrkA receptor protein within the nucleus basalis and cortex in Alzheimer's disease. Exp Neurol (1997) 1.20
Smoking comorbidity in alcoholism: neurobiological and neurocognitive consequences. Alcohol Clin Exp Res (2006) 1.20
A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder. Am J Psychiatry (1999) 1.20
Mecamylamine attenuates the subjective stimulant-like effects of alcohol in social drinkers. Alcohol Clin Exp Res (2003) 1.20
Development of nicotinic drug therapy for cognitive disorders. Eur J Pharmacol (2000) 1.19
Role of different nicotinic acetylcholine receptors in mediating behavioral and neurochemical effects of ethanol in mice. Alcohol (2002) 1.19
Muscarinic receptor subtype pharmacology and physiology. Prog Med Chem (2005) 1.19
Heterogeneity and selectivity of the degeneration of cholinergic neurons in the basal forebrain of patients with Alzheimer's disease. J Comp Neurol (1993) 1.18
Patterns of nicotinic receptor antagonism: nicotine discrimination studies. J Pharmacol Exp Ther (2011) 1.18
Defunctionalized lobeline analogues: structure-activity of novel ligands for the vesicular monoamine transporter. J Med Chem (2005) 3.32
An integrated platform of genomic assays reveals small-molecule bioactivities. Nat Chem Biol (2008) 2.21
14CH4 measurements in Greenland ice: investigating last glacial termination CH4 sources. Science (2009) 2.20
Right-sided Bochdalek hernia obstructing in an adult: case report and review of the literature. Hernia (2007) 1.87
Designing peptide based nanomaterials. Chem Soc Rev (2008) 1.85
Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transporters. J Pharmacol Exp Ther (2004) 1.83
Lobelane decreases methamphetamine self-administration in rats. Eur J Pharmacol (2007) 1.82
Vesicular monoamine transporter 2: role as a novel target for drug development. AAPS J (2006) 1.78
Dosage suppression genetic interaction networks enhance functional wiring diagrams of the cell. Nat Biotechnol (2011) 1.77
The prognostic value of the neutrophil-lymphocyte ratio (NLR) in acute pancreatitis: identification of an optimal NLR. J Gastrointest Surg (2013) 1.70
Impact of margin status on survival following pancreatoduodenectomy for cancer: the Leeds Pathology Protocol (LEEPP). HPB (Oxford) (2009) 1.67
Lobeline does not serve as a reinforcer in rats. Psychopharmacology (Berl) (2002) 1.63
Enzyme-assisted self-assembly under thermodynamic control. Nat Nanotechnol (2008) 1.55
Self-assembled peptide-based hydrogels as scaffolds for anchorage-dependent cells. Biomaterials (2009) 1.52
Lobelane inhibits methamphetamine-evoked dopamine release via inhibition of the vesicular monoamine transporter-2. J Pharmacol Exp Ther (2009) 1.49
The extensive and condition-dependent nature of epistasis among whole-genome duplicates in yeast. Genome Res (2008) 1.44
N,N'-Alkane-diyl-bis-3-picoliniums as nicotinic receptor antagonists: inhibition of nicotine-evoked dopamine release and hyperactivity. J Pharmacol Exp Ther (2008) 1.44
The neutrophil respiratory burst and bacterial digestion in Crohn's disease. Dig Dis Sci (2010) 1.43
Inland thinning of West Antarctic Ice Sheet steered along subglacial rifts. Nature (2012) 1.43
The UCSC Archaeal Genome Browser: 2012 update. Nucleic Acids Res (2011) 1.43
Lobelane analogues as novel ligands for the vesicular monoamine transporter-2. Bioorg Med Chem (2005) 1.38
Prefrontal cortex and drug abuse vulnerability: translation to prevention and treatment interventions. Brain Res Rev (2010) 1.34
The effects of a novel nicotinic receptor antagonist N,N-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB) on acute and repeated nicotine-induced increases in extracellular dopamine in rat nucleus accumbens. Neuropharmacology (2006) 1.32
Environmental enrichment decreases cell surface expression of the dopamine transporter in rat medial prefrontal cortex. J Neurochem (2005) 1.32
Quantum dots and multifunctional nanoparticles: new contrast agents for tumor imaging. Nanomedicine (Lond) (2006) 1.32
Engineering nanoscale order into a designed protein fiber. Proc Natl Acad Sci U S A (2007) 1.31
Oxidative quenching and degradation of polymer-encapsulated quantum dots: new insights into the long-term fate and toxicity of nanocrystals in vivo. J Am Chem Soc (2008) 1.31
Effect of bupropion on nicotine self-administration in rats. Psychopharmacology (Berl) (2003) 1.30
Pyrrolidine analogues of lobelane: relationship of affinity for the dihydrotetrabenazine binding site with function of the vesicular monoamine transporter 2 (VMAT2). J Med Chem (2009) 1.30
Phagocyte dysfunction and inflammatory bowel disease. Inflamm Bowel Dis (2008) 1.29
Environmental enrichment enhances sensitization to GBR 12935-induced activity and decreases dopamine transporter function in the medial prefrontal cortex. Behav Brain Res (2004) 1.27
Robotic multiwell planar patch-clamp for native and primary mammalian cells. Nat Protoc (2009) 1.25
Next-generation quantum dots. Nat Biotechnol (2009) 1.25
Extending the analysis of nicotinic receptor antagonists with the study of alpha6 nicotinic receptor subunit chimeras. Neuropharmacology (2008) 1.25
Lobeline attenuates locomotor stimulation induced by repeated nicotine administration in rats. Pharmacol Biochem Behav (2003) 1.22
The structure and adhesive mechanism of octopus suckers. Integr Comp Biol (2002) 1.18
Semiconductor quantum dots for bioimaging and biodiagnostic applications. Annu Rev Anal Chem (Palo Alto Calif) (2013) 1.18
The pharmacological activity of nicotine and nornicotine on nAChRs subtypes: relevance to nicotine dependence and drug discovery. J Neurochem (2007) 1.18
Pancreatic lesions in von Hippel-Lindau disease? A systematic review and meta-synthesis of the literature. J Gastrointest Surg (2012) 1.17
Behavioral and molecular effects of dopamine D1 receptor stimulation during naloxone-precipitated morphine withdrawal. J Neurosci (2006) 1.17
bis-Azaaromatic quaternary ammonium analogues: ligands for alpha4beta2* and alpha7* subtypes of neuronal nicotinic receptors. Bioorg Med Chem Lett (2002) 1.17
N-n-alkylnicotinium analogs, a novel class of nicotinic receptor antagonists: interaction with alpha4beta2* and alpha7* neuronal nicotinic receptors. J Pharmacol Exp Ther (2003) 1.13
Development of subtype-selective ligands as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release. Bioorg Med Chem Lett (2004) 1.13
Bupropion inhibits nicotine-evoked [(3)H]overflow from rat striatal slices preloaded with [(3)H]dopamine and from rat hippocampal slices preloaded with [(3)H]norepinephrine. J Pharmacol Exp Ther (2002) 1.13
N-n-alkylpyridinium analogs, a novel class of nicotinic receptor antagonists: selective inhibition of nicotine-evoked [3H] dopamine overflow from superfused rat striatal slices. J Pharmacol Exp Ther (2003) 1.12
A comprehensive platform for highly multiplexed mammalian functional genetic screens. BMC Genomics (2011) 1.12
Synthesis and evaluation of a series of homologues of lobelane at the vesicular monoamine transporter-2. Bioorg Med Chem Lett (2008) 1.11
Novel N-1,2-dihydroxypropyl analogs of lobelane inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release. J Pharmacol Exp Ther (2011) 1.10
A pilot study of plasma caffeine concentrations in a US sample of smoker and nonsmoker volunteers. Prog Neuropsychopharmacol Biol Psychiatry (2003) 1.09
Nicotinic receptor-based therapeutics and candidates for smoking cessation. Biochem Pharmacol (2009) 1.09
G6PC3 mutations are associated with a major defect of glycosylation: a novel mechanism for neutrophil dysfunction. Glycobiology (2011) 1.08
The effect of a novel VMAT2 inhibitor, GZ-793A, on methamphetamine reward in rats. Psychopharmacology (Berl) (2011) 1.08
Pharmacokinetics of the novel nicotinic receptor antagonist N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide in the rat. Drug Metab Dispos (2008) 1.07
Synthesis and evaluation of a series of tropane analogues as novel vesicular monoamine transporter-2 ligands. Bioorg Med Chem Lett (2005) 1.06
Methane from the East Siberian Arctic Shelf. Science (2010) 1.06
Carrier-mediated transport of the quaternary ammonium neuronal nicotinic receptor antagonist n,n'-dodecylbispicolinium dibromide at the blood-brain barrier. J Pharmacol Exp Ther (2007) 1.06
N-n-alkylnicotinium analogs, a novel class of nicotinic receptor antagonist: inhibition of S(-)-nicotine-evoked [(3)H]dopamine overflow from superfused rat striatal slices. J Pharmacol Exp Ther (2002) 1.05
Modeling multiple species of nicotine and deschloroepibatidine interacting with alpha4beta2 nicotinic acetylcholine receptor: from microscopic binding to phenomenological binding affinity. J Am Chem Soc (2005) 1.05
Physical chemistry of nanomedicine: understanding the complex behaviors of nanoparticles in vivo. Annu Rev Phys Chem (2015) 1.04
Minimizing nonspecific cellular binding of quantum dots with hydroxyl-derivatized surface coatings. Anal Chem (2008) 1.03
Methylphenidate treatment in adolescent rats with an attention deficit/hyperactivity disorder phenotype: cocaine addiction vulnerability and dopamine transporter function. Neuropsychopharmacology (2010) 1.02
Functional analysis with a barcoder yeast gene overexpression system. G3 (Bethesda) (2012) 1.02
Active transport of high-affinity choline and nicotine analogs into the central nervous system by the blood-brain barrier choline transporter. J Pharmacol Exp Ther (2003) 1.02
Tris-azaaromatic quaternary ammonium salts: Novel templates as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release. Bioorg Med Chem Lett (2007) 1.00
Mecamylamine, dihydro-beta-erythroidine, and dextromethorphan block conditioned responding evoked by the conditional stimulus effects of nicotine. Pharmacol Biochem Behav (2009) 1.00
The novel pyrrolidine nor-lobelane analog UKCP-110 [cis-2,5-di-(2-phenethyl)-pyrrolidine hydrochloride] inhibits VMAT2 function, methamphetamine-evoked dopamine release, and methamphetamine self-administration in rats. J Pharmacol Exp Ther (2010) 1.00
Perioperative complications of the Scarf osteotomy. Foot Ankle Int (2003) 1.00
Discovery of non-peptide, small molecule antagonists of α9α10 nicotinic acetylcholine receptors as novel analgesics for the treatment of neuropathic and tonic inflammatory pain. Bioorg Med Chem Lett (2011) 0.99
Meta-analysis of antecolic versus retrocolic gastric reconstruction after a pylorus-preserving pancreatoduodenectomy. HPB (Oxford) (2014) 0.98
Modeling subtype-selective agonists binding with alpha4beta2 and alpha7 nicotinic acetylcholine receptors: effects of local binding and long-range electrostatic interactions. J Med Chem (2006) 0.98
Defective tumor necrosis factor release from Crohn's disease macrophages in response to Toll-like receptor activation: relationship to phenotype and genome-wide association susceptibility loci. Inflamm Bowel Dis (2012) 0.98
Fmoc-diphenylalanine self-assembly mechanism induces apparent pKa shifts. Langmuir (2009) 0.97
3D-QSAR study of bis-azaaromatic quaternary ammonium analogs at the blood-brain barrier choline transporter. Bioorg Med Chem (2005) 0.96
Effects of environmental enrichment on behavior and dopamine transporter function in medial prefrontal cortex in adult rats prenatally treated with cocaine. Brain Res Dev Brain Res (2004) 0.96
Nicotinic receptor modulation of dopamine transporter function in rat striatum and medial prefrontal cortex. J Pharmacol Exp Ther (2003) 0.95
Adolescence methylphenidate treatment in a rodent model of attention deficit/hyperactivity disorder: dopamine transporter function and cellular distribution in adulthood. Biochem Pharmacol (2013) 0.95
Selective inhibition of acetylcholine-evoked responses of alpha7 neuronal nicotinic acetylcholine receptors by novel tris- and tetrakis-azaaromatic quaternary ammonium antagonists. Mol Pharmacol (2009) 0.94
Indirect trapping of the retroconjugate addition reaction intermediate involved in the epimerization of lobeline: application to the synthesis of (-)-sedamine. J Org Chem (2004) 0.94
Bis-azaaromatic quaternary ammonium salts as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release: An investigation of binding conformation. Bioorg Med Chem Lett (2007) 0.93
QSAR modeling of mono- and bis-quaternary ammonium salts that act as antagonists at neuronal nicotinic acetylcholine receptors mediating dopamine release. Bioorg Med Chem (2006) 0.93
Design, synthesis and interaction at the vesicular monoamine transporter-2 of lobeline analogs: potential pharmacotherapies for the treatment of psychostimulant abuse. Curr Top Med Chem (2011) 0.93
The effect of VMAT2 inhibitor GZ-793A on the reinstatement of methamphetamine-seeking in rats. Psychopharmacology (Berl) (2012) 0.93
Tolerance does not develop to the decrease in nicotine self-administration produced by repeated bupropion administration. Nicotine Tob Res (2005) 0.92
Enzymatic catalyzed synthesis and triggered gelation of ionic peptides. Langmuir (2010) 0.92
Reboxetine: attenuation of intravenous nicotine self-administration in rats. J Pharmacol Exp Ther (2002) 0.92
Small bowel obstruction complicating colonoscopy: a case report. J Med Case Rep (2008) 0.92
Biological connection between novelty- and drug-seeking motivational systems. Nebr Symp Motiv (2004) 0.92
Effect of environmental enrichment on methylphenidate-induced locomotion and dopamine transporter dynamics. Behav Brain Res (2011) 0.91
meso-Transdiene analogs inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release. J Pharmacol Exp Ther (2010) 0.91
A multivariate assessment of individual differences in sensation seeking and impulsivity as predictors of amphetamine self-administration and prefrontal dopamine function in rats. Exp Clin Psychopharmacol (2011) 0.91
Individual differences in response to novelty predict prefrontal cortex dopamine transporter function and cell surface expression. Eur J Neurosci (2007) 0.91
Impaired macrophage function following bacterial stimulation in chronic granulomatous disease. Immunology (2009) 0.91
bPiDI: a novel selective α6β2* nicotinic receptor antagonist and preclinical candidate treatment for nicotine abuse. Br J Pharmacol (2011) 0.91